Evidence map›Paper›PMID 28372922›Full record

ArticleTrends in molecular medicine2017

KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers.

Gary J Doherty, Emma M Kerr, Carla P Martins

Abstract readComment
PubMed Publisher
In one paragraph

Article in Trends in molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Gary J DohertyMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, UK; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Box 193, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
Emma M KerrMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, UK.
Carla P MartinsMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, UK. Electronic address: c.martins@mrc-cu.cam.ac.uk.

Funding

Medical Research Council MC_UU_12022/4
6 · The paper itself

Abstract

The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable.

Indexed as

Allelic ImbalanceBenzamidesDiphenylamineGene DosageHumansLeukemiaMAP Kinase Kinase 1MAP Kinase Kinase 2Models, TheoreticalProto-Oncogene Proteins p21(ras)BenzamidesDiphenylamineMAP2K1 protein, humanMAP2K2 protein, humanMAP Kinase Kinase 1MAP Kinase Kinase 2mirdametinibProto-Oncogene Proteins p21(ras)

Identifiers

PMID28372922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.